Skip to content
10-Q

Quarterly Report

SYROS PHARMACEUTICALS, INC.

0000950170-24-059068

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 7, 2024 26.73M sh
Shares Diluted Q1 2024 · Mar 31, 2024 38.98M sh
Shares Diluted Q1 2024 · Mar 31, 2023 27.84M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$31.1M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$36.9M
Long Term Debt Q1 2024 · Mar 31, 2024 $29.71M
Long Term Debt Q1 2024 · Dec 31, 2023 $34.56M
Short Term Debt Q1 2024 · Mar 31, 2024 $11.67M
Short Term Debt Q1 2024 · Dec 31, 2023 $6.67M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $83.52M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $139.53M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $104.77M
Stockholders Equity Q1 2024 · Mar 31, 2024 $15.06M
Stockholders Equity Q1 2024 · Dec 31, 2023 $16.66M
Stockholders Equity Q1 2024 · Mar 31, 2023 $106.75M
Stockholders Equity Q1 2024 · Dec 31, 2022 $127.74M
Current Liabilities Q1 2024 · Mar 31, 2024 $37.3M
Current Liabilities Q1 2024 · Dec 31, 2023 $36.68M
Current Assets Q1 2024 · Mar 31, 2024 $112.2M
Current Assets Q1 2024 · Dec 31, 2023 $144.98M
Total Assets Q1 2024 · Mar 31, 2024 $134.73M
Total Assets Q1 2024 · Dec 31, 2023 $168.17M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.10
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.85
Eps Basic Q1 2024 · Mar 31, 2024 −$0.10
Eps Basic Q1 2024 · Mar 31, 2023 −$0.85
Sga Expense Q1 2024 · Mar 31, 2024 $6.27M
Sga Expense Q1 2024 · Mar 31, 2023 $7.41M
Rd Expense Q1 2024 · Mar 31, 2024 $24.66M
Rd Expense Q1 2024 · Mar 31, 2023 $28.76M
Net Income Q1 2024 · Mar 31, 2024 −$3.71M
Net Income Q1 2024 · Mar 31, 2023 −$23.79M
Operating Income Q1 2024 · Mar 31, 2024 −$30.92M
Operating Income Q1 2024 · Mar 31, 2023 −$33.21M
Capex Q1 2024 · Mar 31, 2023 $235K
Revenue Q1 2024 · Mar 31, 2023 $2.95M